RANI (ranitherapeutics.com) Rega marang bathi mangsa ngarep
Rani Therapeutics generates revenue through the implementation of innovative drug delivery systems, including the robotic RaniPill capsule. The company's forward P/E ratio history reflects risk cost dynamics, where the value of 0.00 characterizes this level. Geopolitical tensions and logistical disruptions are slowing the progress of testing. Stable management under Talat Imran ensures the precise advancement of technologies through the development stages.
Ringkesan rincian data analitis ranitherapeutics.com (RANI)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- data ekuitas miturut neraca:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Rani Therapeutics|RANI - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Rani Therapeutics Holdings|RANI - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Rani Therapeutics|RANI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Rani Therapeutics|Likuiditas cepet ranitherapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
RANI - Bathi perusahaan|Proyeksi bathi mangsa ngarep Rani Therapeutics|RANI - Periode bali modal bisnis|Prakiraan rega marang bathi Rani Therapeutics Holdings|RANI - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Rani Therapeutics Holdings|RANI - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Rani Therapeutics|RANI - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan ranitherapeutics.com|RANI - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Rani Therapeutics
- statistik dodolan lan pendapatan perusahaan:
Pambiji fundamental:RANI Rani Therapeutics
The forward P/E reflects the market value of the asset relative to projected net income, allowing for an assessment of the premium paid for expected business growth. By analyzing the forward P/E of Rani Therapeutics (RANI), an investor views capitalization through the lens of the efficiency of RaniPill robotic lines, where the automation of biologic encapsulation in clean rooms is expected to scale margins and reduce operating expenses.
Pesaing langsung
Rega marang bathi mangsa ngarep haleon.com (HLN)|KVUE (Kenvue Health) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Rasio prakiraan rega marang bathi|LGND: Prakiraan rega marang bathi|Amneal - Rasio kapitalisasi marang bathi mangsa ngarep|PRGO: Pangali Forward P/E|Alvotech Corp - Pangali mangsa ngarep rega marang bathi|LQDA (Liquidia Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi glpg.com GLPG|Rega marang bathi mangsa ngarep ANI Pharmaceuticals, Inc. (ANIP)|MNKD (MannKind Corp) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E AMPH (Amphastar Pharmaceuticals Inc)|PCRX (Pacira) - Rasio rega marang bathi sing dikarepake|SPRY - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi TBPH (Theravance Biopharma)|AQST (aquestive.com) - Prakiraan rega marang bathi|Rasio rega marang bathi sing dikarepake SCPH (scPharmaceuticals, Inc.)|Prakiraan rega marang bathi TECX|Tonix Pharmaceuticals (TNXP) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E SXTC|Pangali Forward P/E Eupraxia Pharma (EPRX)|Rega marang bathi mangsa ngarep BioHarvest Sciences Inc. BHST|EXOZ - Prakiraan rega marang bathi|ORMP: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi abvcpharma.com (ABVC)|Rega marang bathi mangsa ngarep Cumberland Pharma|Rega marang bathi mangsa ngarep QNTM|Pangali Forward P/E FGEN|TELO (Telomir Pharma) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Rasio prakiraan rega marang bathi|LEXX - Rega marang bathi mangsa ngarep|PULM (Pulmatrix) - Rasio rega marang bathi mangsa ngarep|Pheton Holdings Ltd (PTHL) - Rega marang bathi mangsa ngarep|Aptorum - Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi LYRA|Prakiraan rega marang bathi Impact BioMedical Inc (IBO)|Pangali Forward P/E TNFA|YCBD: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep PainReform PRFX|altamiratherapeutics.com (CYTO) - Rasio prakiraan rega marang bathi|LIPO: Prakiraan rega marang bathi|OPTN (optinose.com) - Rasio rega marang bathi mangsa ngarep|PIRS: Pangali Forward P/E|PROC - Kapitalisasi marang proyeksi bathi|PTPI (Petros Pharma) - Pangali Forward P/E|Rega marang bathi mangsa ngarep QLI|Pangali Forward P/E SLRN|Rasio kapitalisasi marang bathi mangsa ngarep TFFP
